<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220822055773N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-08-31</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Comparative evaluation of surgical result of sonographic assisted minimally invasive parathyroidectomy And conventional parathyroidectomy in primary hyparathyroidisem patients</public_title>
      <acronym></acronym>
      <scientific_title>Comparative evaluation of surgical result of sonographic assisted minimally invasive parathyroidectomy And conventional parathyroidectomy in primary hyparathyroidisem patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2016-08-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>96</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/65477</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization method: It is simple, a number was assigned to each patient, then they were placed in the online platform www.randomization.com to randomize the number, and two groups A and B were randomized as intervention and control groups.
Randomization Unit: Individual
Output of the random instrument: patients with primary hyperthyroidism who have been definitively diagnosed clinically and laboratory, both male and female, without age limit.</study_design>
      <phase>3</phase>
      <hc_freetext>surgical result of sonographic assisted minimally invasive parathyroidectomy And conventional parathyroidectomy in primary hyparathyroidisem patients.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In this study, the patients entered the study after being selected based on the entry and exit criteria, then pre-operative tests and examinations for MIP (minimally invasive parathyroidectomy) candidates, including ultrasound examination to localize the overactive parathyroid and serum measurement of the PTH hormone level. During the operation and scanning of the parathyroid will be performed and finally the surgery will be performed in a minimally invasive way to remove the overactive parathyroid. Then necessary tests such as PTH measurement before surgical incision, PTH measurement before excision, PTH measurement 5 minutes after excision and finally PTH measurement 10 minutes after excision will be measured. Intervention 2: Control group: In this study, the patients entered the study after being selected based on the entry and exit criteria, then pre-operative tests and examinations for conventional parathyroidectomy candidates, including the serum measurement of the PTH hormone level during the operation and the parathyroid scan, will be performed. Finally, conventional surgery will be performed to remove the overactive parathyroid. Then necessary tests such as PTH measurement before surgical incision, PTH measurement before excision, PTH measurement 5 minutes after excision and finally PTH measurement 10 minutes after excision will be measured. In patients who are candidates for parathyroidectomy by conventional method, parathyroid scan and ultrasound will be used to localize the overactive parathyroid before the operation.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Data will be shared after blinding of datasheet.

When:
Data will be shared within 6 months after publication.

To whom:
Data will be accessible for researchers affiliated to universities

Conditions:
Data can be used for further meta-analysis after permission of the person responsible for this project

Where to obtain:
Data request should be sent through email for the person responsible for this project. Dr. Shirzad Nasiri Zivaki Dr.sh.nasiri@gmail.com

How to obtain:
Following the primary request, all the researchers will be informed by the responsible person and after permission the data will be shared.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Shirzad Nasiri Zaviki</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Jalal Al Ahmad Three Roads, North Kargar St.,</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1411713135</zip>
        <telephone>+98 21 8863 3039</telephone>
        <email>Dr.sh.nasiri@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Shirzad Nasiri Zaviki</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Jalal Al Ahmad Three Roads, North Kargar St.,</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1411713135</zip>
        <telephone>+98 21 8863 3039</telephone>
        <email>Dr.sh.nasiri@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients with primary hyperthyroidism</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients whose parathyroid tumor is more than 4 cm
The presence of any chronic disease or malignancy in the thyroid or parathyroid region or suffering from any systemic and malignant disease
Patients with secondary or tertiary hyperthyroidism</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E21.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Primary hyperparathyroidism</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In this study, the patients entered the study after being selected based on the entry and exit criteria, then pre-operative tests and examinations for MIP (minimally invasive parathyroidectomy) candidates, including ultrasound examination to localize the overactive parathyroid and serum measurement of the PTH hormone level. During the operation and scanning of the parathyroid will be performed and finally the surgery will be performed in a minimally invasive way to remove the overactive parathyroid. Then necessary tests such as PTH measurement before surgical incision, PTH measurement before excision, PTH measurement 5 minutes after excision and finally PTH measurement 10 minutes after excision will be measured.</i_keyword>
      <i_keyword>Control group: In this study, the patients entered the study after being selected based on the entry and exit criteria, then pre-operative tests and examinations for conventional parathyroidectomy candidates, including the serum measurement of the PTH hormone level during the operation and the parathyroid scan, will be performed. Finally, conventional surgery will be performed to remove the overactive parathyroid. Then necessary tests such as PTH measurement before surgical incision, PTH measurement before excision, PTH measurement 5 minutes after excision and finally PTH measurement 10 minutes after excision will be measured. In patients who are candidates for parathyroidectomy by conventional method, parathyroid scan and ultrasound will be used to localize the overactive parathyroid before the operation.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Success of MIP surgery in patients with primary hyperparathyroidism based on changes in serum PTH levels. Timepoint: PTH measurement before surgical incision, PTH measurement before excision, PTH measurement 5 minutes after excision and finally PTH measurement 10 minutes after excision. Method of measurement: Sonographic investigation to localize overactive parathyroid and serum level of PTH during surgery and parathyroid scan.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2016-08-22</approval_date>
        <contact_name>Tehran university of medical sciences ethics committee</contact_name>
        <contact_address>Tehran University of Medical Sciences, Poursina Avenue, Qods Street, Enqelab Square, Tehran, Iran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
